UPDATE: Citigroup Lowers PT on Abbott Laboratories Following In-Line 2Q13 Results
July 19, 2013 at 08:59 AM EDT
In a report published Friday, Citigroup analyst Matthew J. Dodds reiterated a Sell rating on Abbott Laboratories (NYSE: ABT ), and lowered the price target from $33.00 to $31.00. In the report, Citigroup noted, “ABT's sales came in a bit light for the 2nd straight quarter and were in line
